PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
INCR vs. TEVA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between INCR and TEVA is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

INCR vs. TEVA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in INC Research Holdings Inc (INCR) and Teva Pharmaceutical Industries Limited (TEVA). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025
-10.43%
6.30%
INCR
TEVA

Key characteristics

Sharpe Ratio

INCR:

0.45

TEVA:

1.16

Sortino Ratio

INCR:

1.31

TEVA:

2.16

Omega Ratio

INCR:

1.15

TEVA:

1.28

Calmar Ratio

INCR:

0.38

TEVA:

0.62

Martin Ratio

INCR:

0.89

TEVA:

8.83

Ulcer Index

INCR:

40.29%

TEVA:

5.79%

Daily Std Dev

INCR:

80.16%

TEVA:

44.17%

Max Drawdown

INCR:

-94.32%

TEVA:

-90.80%

Current Drawdown

INCR:

-90.84%

TEVA:

-73.53%

Fundamentals

Market Cap

INCR:

$74.60M

TEVA:

$20.16B

EPS

INCR:

-$0.40

TEVA:

-$1.45

Total Revenue (TTM)

INCR:

$125.73M

TEVA:

$16.56B

Gross Profit (TTM)

INCR:

$41.66M

TEVA:

$8.07B

EBITDA (TTM)

INCR:

$14.40M

TEVA:

$480.00M

Returns By Period

In the year-to-date period, INCR achieves a 2.52% return, which is significantly higher than TEVA's -19.56% return.


INCR

YTD

2.52%

1M

-1.58%

6M

-22.01%

1Y

35.83%

5Y*

-21.47%

10Y*

N/A

TEVA

YTD

-19.56%

1M

-16.53%

6M

4.36%

1Y

44.38%

5Y*

8.05%

10Y*

-10.39%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

INCR vs. TEVA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

INCR
The Risk-Adjusted Performance Rank of INCR is 6363
Overall Rank
The Sharpe Ratio Rank of INCR is 6464
Sharpe Ratio Rank
The Sortino Ratio Rank of INCR is 6868
Sortino Ratio Rank
The Omega Ratio Rank of INCR is 6363
Omega Ratio Rank
The Calmar Ratio Rank of INCR is 6464
Calmar Ratio Rank
The Martin Ratio Rank of INCR is 5858
Martin Ratio Rank

TEVA
The Risk-Adjusted Performance Rank of TEVA is 8282
Overall Rank
The Sharpe Ratio Rank of TEVA is 8282
Sharpe Ratio Rank
The Sortino Ratio Rank of TEVA is 8383
Sortino Ratio Rank
The Omega Ratio Rank of TEVA is 8282
Omega Ratio Rank
The Calmar Ratio Rank of TEVA is 7272
Calmar Ratio Rank
The Martin Ratio Rank of TEVA is 9090
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

INCR vs. TEVA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for INC Research Holdings Inc (INCR) and Teva Pharmaceutical Industries Limited (TEVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for INCR, currently valued at 0.45, compared to the broader market-2.000.002.000.451.16
The chart of Sortino ratio for INCR, currently valued at 1.31, compared to the broader market-4.00-2.000.002.004.001.312.16
The chart of Omega ratio for INCR, currently valued at 1.15, compared to the broader market0.501.001.502.001.151.28
The chart of Calmar ratio for INCR, currently valued at 0.38, compared to the broader market0.002.004.006.000.381.28
The chart of Martin ratio for INCR, currently valued at 0.89, compared to the broader market0.0010.0020.0030.000.898.83
INCR
TEVA

The current INCR Sharpe Ratio is 0.45, which is lower than the TEVA Sharpe Ratio of 1.16. The chart below compares the historical Sharpe Ratios of INCR and TEVA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00SeptemberOctoberNovemberDecember2025
0.45
1.16
INCR
TEVA

Dividends

INCR vs. TEVA - Dividend Comparison

Neither INCR nor TEVA has paid dividends to shareholders.


TTM20242023202220212020201920182017201620152014
INCR
INC Research Holdings Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
TEVA
Teva Pharmaceutical Industries Limited
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%4.49%3.75%2.07%2.38%

Drawdowns

INCR vs. TEVA - Drawdown Comparison

The maximum INCR drawdown since its inception was -94.32%, roughly equal to the maximum TEVA drawdown of -90.80%. Use the drawdown chart below to compare losses from any high point for INCR and TEVA. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025
-90.84%
-22.13%
INCR
TEVA

Volatility

INCR vs. TEVA - Volatility Comparison

The current volatility for INC Research Holdings Inc (INCR) is 9.66%, while Teva Pharmaceutical Industries Limited (TEVA) has a volatility of 17.14%. This indicates that INCR experiences smaller price fluctuations and is considered to be less risky than TEVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025
9.66%
17.14%
INCR
TEVA

Financials

INCR vs. TEVA - Financials Comparison

This section allows you to compare key financial metrics between INC Research Holdings Inc and Teva Pharmaceutical Industries Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab